• 1
    Clauw DJ, Pincus T. The eosinophilia-myalgia syndrome: what we know, what we think we know, and what we need to know. J Rheumatol Suppl 1996; 46: 26.
  • 2
    Belongia EA, Hedberg CW, Gleich GJ, White KE, Mayeno AN, Loegering DA, et al. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med 1990; 323: 35765.
  • 3
    Kamb ML, Murphy JJ, Jones JL, Caston JC, Nederlof K, Horney LF, et al. Eosinophilia-myalgia syndrome in L-tryptophan-exposed patients. JAMA 1992; 267: 7782.
  • 4
    Back EE, Henning KJ, Kallenbach LR, Brix KA, Gunn RA, Melius JM. Risk factors for developing eosinophilia myalgia syndrome among L-tryptophan users in New York. J Rheumatol 1993; 20: 66672.
  • 5
    Horwitz RI, Daniels SR. Bias or biology: evaluating the epidemiologic studies of L-tryptophan and the eosinophilia-myalgia syndrome. J Rheumatol Suppl 1996; 46: 6072.
  • 6
    Shapiro S. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique. J Rheumatol Suppl 1996; 46: 4459.
  • 7
    Clauw DJ, Flockhart DA, Mullins W, Katz P, Medsger TA Jr. Eosinophilia-myalgia syndrome not associated with the ingestion of nutritional supplements. J Rheumatol 1994; 21: 23857.
  • 8
    Sullivan EA, Staehling N, Philen RM. Eosinophilia-myalgia syndrome among the non-L-tryptophan users and pre-epidemic cases. J Rheumatol 1996; 23: 17847.
  • 9
    Kaufman LD, Gruber BL, Gregersen PK. Clinical follow-up and immunogenetic studies of 32 patients with eosinophilia-myalgia syndrome. Lancet 1991; 337: 10714.
  • 10
    Flockhart DA, Clauw DJ, Sale EB, Hewett J, Woosley RL. Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome. Clin Pharmacol Ther 1994; 56: 398405.
  • 11
    Begovich AB, McClure GR, Suraj VC, Helmuth RC, Fildes N, Bugawan TL, et al. Polymorphism, recombination, and linkage disequilibrium within the HLA class II region. J Immunol 1992; 148: 24958.
  • 12
    Shamim EA, Rider LG, Pandey JP, O'Hanlon TP, Jara LJ, Samayoa EA, et al. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum 2002; 46: 188593.
  • 13
    Miranda-Malpica E, Martinez-Rios MA, Fragoso JM, Delgadillo-Rodriguez H, Rodriguez-Perez JM, Gonzalez-Quesada C, et al. The interleukin 1B-511 polymorphism is associated with the risk of developing restenosis after coronary stenting in Mexican patients. Hum Immunol 2008; 69: 11621.
  • 14
    Heinze G. A comparative investigation of methods for logistic regression with separated or nearly separated data. Stat Med 2006; 25: 421626.
  • 15
    Maiti T, Pradhan V. A comparative study of the bias corrected estimates in logistic regression. Stat Methods Med Res 2008; 17: 62134.
  • 16
    Varga J, Uitto J, Jimenez SA. The cause and pathogenesis of the eosinophilia-myalgia syndrome. Ann Intern Med 1992; 116: 1407.
  • 17
    Pincus T. Eosinophilia-myalgia syndrome: patient status 2-4 years after onset. J Rheumatol Suppl 1996; 46: 1925.
  • 18
    Ginn LR, Lin JP, Plotz PH, Bale SJ, Wilder RL, Mbauya A, et al. Familial autoimmunity in pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors for many autoimmune diseases. Arthritis Rheum 1998; 41: 4005.
  • 19
    Prelog M. Aging of the immune system: a risk factor for autoimmunity? Autoimmun Rev 2006; 5: 1369.
  • 20
    Candore G, Lio D, Colonna RG, Caruso C. Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions. Autoimmun Rev 2002; 1: 2935.
  • 21
    Barth H, Klein R, Berg PA. L-tryptophan contaminant ‘peak E’ induces the release of IL-5 and IL-10 by peripheral blood mononuclear cells from patients with functional somatic syndromes. Clin Exp Immunol 2001; 126: 18792.
  • 22
    Del Pozo V, de Andres B, Gallardo S, Cardaba B, de Arruda-Chaves E, Cortegano MI, et al. Cytokine mRNA expression in lung tissue from toxic oil syndrome patients: a TH2 immunological mechanism. Toxicology 1997; 118: 6170.
  • 23
    Arnaiz-Villena A, Martinez-Laso J, Corell A, Allende L, Rosal M, Gomez-Reino JJ, et al. Frequencies of HLA-A24 and HLA-DR4-DQ8 are increased and that of HLA-B blank is decreased in chronic toxic oil syndrome. Eur J Immunogenet 1996; 23: 2119.